Guerbet
France - VillepinteBiotechnology
Focus: Guerbet is a specialized pharmaceutical company focused on contrast agents and injectors for diagnostic imaging across oncology, nephrology, cardiovascular, gastroenterology, and neurology. As a publicly traded French company headquartered in Villepinte, it holds a niche but established position in the medical imaging market.
Profile data last refreshed 16h ago · AI intelligence enriched 1w ago
Funding Stage
PUBLIC
Open Jobs
0
About Guerbet
AI assessmentNot HiringNo open roles listed right now. Follow Guerbet to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Guerbet's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
5/9 — Partial
Company HealthStrong
Pipeline
Late-stage
9 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Peak
Flagship MRI contrast agent at peak commercial maturity; demonstrates strong MOA in T1-weighted imaging and forms the backbone of Guerbet's revenue.
Help build intelligence for Guerbet
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.